01—Abstract
Summary
Summary of the 8-K filed May 14, 2025. Cited figures are marked; the original filing is the authoritative source.
UnitedHealth Group (UNH) disclosed in this May 14, 2025 Form 8-K that CEO Andrew Witty stepped down effective May 12, 2025, and that the Board appointed Stephen J.
Hemsley, a former CEO (2006-2017) who has been Board chair since 2017, as CEO. Hemsley remains Chair and stops receiving director compensation. Witty will serve as a senior advisor to Hemsley.
The Board and Compensation Committee approved Hemsley's pay package: a $1,000,000a base salary, no annual cash incentive, a one-time $60 million nonqualified stock option grant with cliff vesting after three years, and no additional annual equity awards during his first three years. Severance is two times salary and bonus plus 24 months of option vesting, conditioned on a non-compete. The large one-time equity grant is a strong signal of the Board's intent to align Hemsley's incentives with a turnaround.
The more consequential news for investors is the May 13, 2025 press release (Exhibit 99.1), which suspended the company's 2025 outlook. Management cited medical expenditures running higher than anticipated, as care activity accelerated and spread to more benefit types than in the first quarter, and medical costs for many Medicare Advantage beneficiaries new to UnitedHealthcare stayed elevated. The company said it expects a return to growth in 2026 and reiterated a long-term growth objective of 13%b to 16%.
Taken together, the filing reflects a sharp leadership change coinciding with a guidance withdrawal driven by medical cost pressure. Investors should weigh the reassurance of an experienced returning leader against the near-term uncertainty over earnings visibility, the sustainability of medical cost trends, and the timing of the expected 2026 recovery. The filing does not quantify the earnings impact of the suspended outlook, and the leadership details are incorporated by reference to the 2025 proxy statement.
02—Key points
Key Highlights
- CEO transition: Andrew Witty stepped down effective May 12, 2025; Stephen J. Hemsley, CEO from 2006-2017 and Board chair since 2017, was appointed CEO and remains Chair.
- Guidance suspended: The company suspended its 2025 outlook because medical expenditures are expected to be higher than anticipated.
- Cost drivers: Care activity accelerated and broadened to more benefit types than in Q1, and Medicare Advantage members new to UnitedHealthcare continued to have higher-than-expected medical costs.
- Recovery target: Management expects to return to growth in 2026 and reiterated its long-term growth objective of 13% to 16%.
- CEO compensation: $1M base salary, no annual cash incentive, and a one-time $60M nonqualified stock option grant with three-year cliff vesting; no additional annual equity for three years.
- Severance terms: 2x base salary plus 2x bonus (if any) and 24 months of continued option vesting, conditioned on a non-compete and triggered only by termination without cause or for good reason.
- Advisory role for Witty: Andrew Witty will continue as a senior advisor to the new CEO, supporting continuity during the transition.
03—Questions
Frequently Asked Questions
Why did UnitedHealth suspend its 2025 outlook?
Management said medical expenditures are expected to be higher than anticipated. Care activity accelerated and spread to more types of benefits than seen in the first quarter, and the medical costs of many Medicare Advantage beneficiaries new to UnitedHealthcare remained higher than expected.
Who is the new CEO and what is his background?
Stephen J. Hemsley was named CEO effective immediately. He served as CEO from 2006 to 2017, joined the company as chief operating officer in 1997, became president in 1999, and has chaired the Board since 2017. He will continue as Chair.
What is the new CEO's compensation package?
The package includes a $1,000,000 annual base salary and no annual cash incentive. It also includes a one-time $60 million nonqualified stock option grant that cliff-vests after three years, with no additional annual equity awards during his first three years.
Does the company expect a recovery?
Management said it expects to return to growth in 2026 and reaffirmed its long-term growth objective of 13% to 16%. The filing does not provide quantitative 2026 guidance.
What does the filing mean for Andrew Witty?
Witty stepped down as CEO effective May 12, 2025, citing personal reasons, and will serve as a senior advisor to Hemsley. The filing does not disclose any separation payments for Witty.
04—Continue